Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Amryt Pharma Plc LSE:AMYT London Ordinary Share GB00BKLTQ412 ORD 6P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 167.50 165.00 170.00 167.50 167.50 167.50 3,400 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 49.2 -56.5 -72.8 - 300

Amryt Pharma Share Discussion Threads

Showing 4351 to 4369 of 6725 messages
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
DateSubjectAuthorDiscuss
08/2/2019
13:02
NEW article out guys ... Amryt Pharma adds new element to promising portfolio 11:15 08 Feb 2019 “If successful, this platform [AP103] has potential in other genetic skin conditions and beyond” [...] Junior with one drug on the market and second in phase III trial Cholesterol treatment Lojuxta on sale in five major European countries AP101 in phase III trial for Epidermolysis Bullosa (EB), a condition which occurs prominently in children and makes skin fragile to even the faintest touch. Independent committee recommends trial continues with modest increaser in number of patients No other available treatment in EB market worth US$1bn How is it doing AP101 is a skin disorder treatment for epidermolysis bullosa, a rare, inherited condition which occurs predominantly in children and makes skin fragile to even the faintest touch. It is chronic, potentially disfiguring and in some cases fatal. There are around 500,000 people living with EB worldwide and there are currently no approved treatments. After analysing interim efficacy data, the Independent Data Monitoring Committee (IDMC) has recommended Amryt continues the phase III study but with the addition of 48 new patients. That will take the total up to 230 and the larger pool should yield better, more reliable data further down the line. Lojuxta is an approved treatment for adult patients with the rare cholesterol disorder - Homozygous Familial Hypercholesterolaemia (HoFH). This disorder impairs the body's ability to remove low-density lipoprotein (LDL) cholesterol ("bad" cholesterol) from the blood, typically leading to abnormally high blood LDL cholesterol levels in the body from before birth. Amryt has exclusive licences for the European Economic Area, Middle East and North Africa, Switzerland, Turkey, Israel, Russia, the Commonwealth of Independent States and the non-EU Balkan states. Lojuxta’s revenues for the six months to June amounted to €6.6mln or a 14.6% increase from the same period in 2017. Group revenues rose by 13.6% to €7mln from €6.2mln a year earlier. Losses in half-year were €11.4mln while cash holdings were €12.2mln. AP103 In January, Amryt Pharma PLC (LON:AMYT) said a pre-clinical study of a cream for a severe and very difficult to treat skin condition has delivered encouraging results. AP103 is a putative treatment for recessive dystrophic epidermolysis bullosa (RDEB), which is a subset of epidermolysis bullosa (EB), a condition that means the skin is so fragile it breaks at the lightest contact. Researchers carried out in vitro, or lab tests as well as applying AP103 onto a 3-D matrix of human RDEB skin. The headline results revealed the cream restored the production of collagen VII to levels exceeding those created by healthy people. Collagen VII is critical in the wound healing process and scientists believe it could have a central role to play in tackling REDB. AP103 has been awarded grant funding totalling €8.4m over three years by the Irish government. What the boss says: Joe Wiley "Initiation of the first trial site in the US allows us to further accelerate patient enrolment for EASE and crucially, means that eligible American sufferers of this rare condition will be able to take part in this potentially life-changing trial.”
ih_116147
08/2/2019
08:28
You’re being daft!
bazworth
08/2/2019
08:10
Guys just bomb them with emails to put them under pressure . I have send 3 emails in last 2 days . Tell them that youre very frustrated about the share price and that they should do more updates and PR .I did that also on FUM and other companies you must put them under pressure sometimes it works . IR@amrytpharma.com
ih_116147
07/2/2019
16:41
It all depends on the news, good, or bad, that AMYT releases, mdalos. You pays your money, you takes your choice.
papillon
07/2/2019
14:44
"Im sure that this sleeping giant will also awake soon" I'm in total agreement, bioking. I originally bought into FAST in early 2015 (around 2p, currently = to 16p after the 1 for 8 consolidation) when it was a cash shell and selling at a big percentage discount to it's cash. I had hoped that the cash would be returned to shareholders, but no such luck! I've hung around ever since, topping up along the way. Sometimes judiciously such as in November and others times injudiciously! I'm still marginally up, but nothing to boast about! I could have made an excellent profit, bioking, if I had had the sense to sell my shares back in April/May 2017 as the shares rose from a low of circa 14p to a high of 27p in around 5 months following the 2 good RNS's in December 2016 concerning the EIB loan & Lojuxta licensing deal. So it would have been possible to make a good profit out of AMYT in the early stages, but only if you had bought after the share price dropped significantly from the IPO of 24p. Of course the rise from the 2016 low of circa 14p to the 2017 high of 27p was completely dependent on good news. Good news drives up sp's and we might have to wait some time yet for good news. Hopefully NOT!
papillon
07/2/2019
13:09
3 years ago everything was in early stage and thats not the best time to invest in biotechs but now we have AP101 phase 3 readout in sight and the lojuxta sales growing now is a excellent entry point .My strategy in Biotechs is only to invest when they are close to their major milestones like Phase 3 readout or Approval of a drug and this has paid off for me just look at fum thats just one example . Im sure that this sleeping giant will also awake soon .
bioking
07/2/2019
12:52
Actually, bioking, the CHEMICAL name is LOMITAPIDE. It was developed by Aegerion and they initially MARKETED it with the brand name JUXTAPID in the USA. They only gave Lomitapide the brand name Lojuxta when it was approved for sale in Europe. Hence Juxtapid predated Lojuxta as a brand name for Lomitapide. https://en.wikipedia.org/wiki/Lomitapide
papillon
07/2/2019
12:45
bioking. AMYT can't sell Lojuxta in North America, South America & JAPAN. Why? Because Novelion (Aegerion) retained the rights to sell Juxtapid in those markets when they licensed Lojuxta to AMYT in early December 2016. AMYT were licensed to sell Lojuxta ONLY in Europe, North Africa & the Middle East. Look back over the RNS's for AMYT over the past few years, bioking. They have signed many such deals with distributors in Europe & the Middle East similar to the deal Novelion have just announced with a distributor in Japan, for which you have provided a link. None of these RNS's from AMYT generated much interest from investors and had very little effect on the AMYT share price You mentioned the fact that Harry Stratford, of Shire fame, is the chairman of AMYT and a plus point for the company. I and others have been pointing that out on this bb ever since AMYT floated nearly 3 years ago. It hasn't noticeably had any positive effect on the share price What has caused the share price to spike up has been good news, such as the EIB loan and Lojuxta licensing deal. In fact Harry Stratford didn't initially have any shares in AMYT. He didn't partake in the initial 24p placing. However he partook in the 20p placing of September 2016, but only invested a very small sum for a man of his undoubted wealth.
papillon
07/2/2019
12:30
nope the real name is lomitapid which sold as juxtapid in US and lojuxta in Europe whatever that doesnt care its just the name .
bioking
07/2/2019
12:01
How does that benefit AMYT, bioking? You have written .. "Lojuxta also known as Juxtapid" That's WRONG, bioking. You should have written "Juxtapid also known as Lojuxta". Why? The original brand name was Juxtapid. It was sold as Juxtapid in the USA. When Aegerion obtained approval to sell the drug in Europe they marketed Juxtapid as Lojuxta. When Aegerion ran into serious financial difficulties because of past miss-selling of Juxtapid they were "rescued" by Novelion and the European marketing operation of Aegerion which was selling Lojuxta was closed down and Lojuxta was licensed to AMYT.
papillon
07/2/2019
09:20
Aegerion licenses Japan rights of Lojuxta also known as Juxtapid out to Recordati for $25 million upfront .Recordati is a big player in the rare disease area so they must see big potential in the drug . Amyt owns rights to the way larger Europe Market and in some countries outside . https://finance.yahoo.com/news/novelion-therapeutics-subsidiary-enters-licensing-073000564.html Under the terms of the agreement, Aegerion will receive a $25 million upfront payment, and an additional $5 million upon transfer of the JUXTAPID marketing authorization in Japan to Recordati. Commercial milestone payments of up to an additional $80 million in the aggregate may become payable to Aegerion in prescribed increments, beginning at the end of the first quarter in which cumulative net sales in Japan reach $70 million, and continuing for each increase in cumulative net sales of $70 million thereafter, until cumulative net sales in Japan reach $700 million.
bioking
07/2/2019
08:41
The FUM share price has almost QUADRUPLED in the past 5 weeks. Evidently it's developing products to help men achieve an erection! Going by the recent FUM share price performance the share price has definitely achieved a HARD ON! LOL.
papillon
07/2/2019
08:35
bioking 7 Feb '19 - 08:06 - 5009 of 5009 0 0 0 rallyyyyyyyyyyyyyyyyy now next near term number is 30p >>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>>> Since bioking is still busy ramping FUM this morning and talking of 30p in the "near term", I doubt he's selling any FUM to put into AMYT, bazworth! LOL.
papillon
07/2/2019
08:07
bioking, was that your buy from profits already gone through......! Tee hee!
bazworth
07/2/2019
08:02
Fantastic!!
bazworth
07/2/2019
07:05
will take some profit from my fum investment and add more amyt . this stock has really massive upside potential and i like the fact tha Shire founder is on board of amyt .
bioking
06/2/2019
13:06
Everything crossed here too. Best I uncross before getting the bicycle out this afternoon!! Cheers Baz
bazworth
06/2/2019
12:16
Well obviously, bioking, brokers holding customers shares in nominee a/c's will loan out the shares for a fee, given the opportunity, to "shorters". So what? Good news will drive the AMYT share price up despite the efforts of any "shorters". I'm not convinced that there is widespread shorting of AMYT. In fact I know of no evidence that AMYT is being shorted. Have you any such evidence, bioking? I've read articles saying that there are lists of heavily shorted shares in the public domain, but I've never heard of AMYT being on that list, bioking. In fact if anyone is brave enough to short AMYT they are taking an almighty risk. We had a trading update released in the middle of March last year and the Final results in the middle of April. Not long to wait for news. Hopefully we'll get good news before then, but there is also the possibility of bad news being released instead (another placing). I'm gambling on good news! Fingers crossed.
papillon
06/2/2019
11:17
If you guys want the stock to make bigger moves then please put your shares on high GTC sell order like 50p this helps to prevent your shares from being shorted and more important your shares will not be available on the market so if all shareholders doing that then it would help this stock to make bigger jumps in share price on good news. thank you hxxps://www.contracts-for-difference.com/Borrowing-lending-shares.html Q:What can you do to prevent your shares holdings from being shorted? A: Now what can the average personal investor do to stop their own shares being shorted, as believe me your own broker, if approached, WILL sell your own shares that they hold on your behalf as a nominee account. There are two things you can do, the first is to certificate them but this is not obviously to everyone’s advantage but the alternative solution is simple. All you do is to phone your broker and put an order in saying that you wish to place your shares for sale at, for arguments sake, double today’s price. As they are ‘on order’ they cannot be lent out by your broker and in turn you are reducing the amount of ‘free shares’ out there that can be used for shorting purposes. And don’t forget to move your limit order up when the price starts to recover, then, that way your shares can’t be shorted – not much but helps :D. Although an individual personal investor will not normally have enough shares to halt a concerted shorting attack, if a large number of holders did this it would reduce the overall amount of shares that they could get their hands on. In my opinion well worth doing if not only for the knowledge that your own shares cannot and will not be used in a short attack against the very share that you own.
bioking
Chat Pages: Latest  185  184  183  182  181  180  179  178  177  176  175  174  Older
ADVFN Advertorial
Your Recent History
LSE
AMYT
Amryt Phar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210723 20:24:11